Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden

Epke A Le Rutte PhD[*] [a,b], Andrew J Shattock PhD[*] [a,b], Nakul Chitnis PhD [a,b], Sherrie L Kelly PhD [a,b], Melissa A Penny PhD [a,b]

[a] Swiss Tropical and Public Health Institute, Basel, Switzerland

[b] University of Basel, Basel, Switzerland

[*] These authors contributed equally to this work

Correspondence to Prof Melissa A Penny

melissa.penny@unibas.ch

Summary

SARS-CoV-2 variant Omicron (B.1.1.529) was classified as a variant of concern (VOC) on November 26, 2021. (1, 2) The infectivity, severity, and immune evasion properties of Omicron relative to the Delta variant will determine 1) the probability of dominant future transmission, and 2) the impact on disease burden. (3, 4) Here we apply an individual-based transmission model to identify thresholds for Omicron's potential dominance, impact on health, and risk to health systems; and identify for which combinations of viral properties, current interventions would be sufficient to control transmission. We show that, with first-generation SARS-CoV-2 vaccines (5) and limited physical distancing in place, the threshold for Omicron's future dominance will primarily be driven by its degree of infectivity. However, Omicron's potential dominance may not necessarily lead to increased public health burden. Expanded vaccination that includes a third-dose for adults and child vaccination strategies is projected to have the biggest public health benefit for a highly infective, highly severe variant with low immune evasion capacity. However, a highly immune evading variant that becomes dominant will likely require alternative measures for control, such as strengthened physical distancing measures, novel treatments, and second-generation vaccines. These findings provide quantitative guidance to decision-makers at a critical time while Omicron properties are being assessed. (6) We emphasize the importance of both genomic and population epidemiological surveillance.

Introduction

SARS-CoV-2 has been mutating continuously since its emergence in December 2019, leading to viral variants with varying infectivity, severity, and immune evading properties. On 26 November 2021, the World Health Organization identified Omicron (B.1.1.529) as a new variant of concern (VOC) after approximately seven months of Delta variant (B.1.617.2) dominating global transmission. (1) Within one week, 24 countries had reported cases of the Omicron variant, (7) with infections also occurring in previously infected and double-vaccinated individuals. (8) Whilst scientific research assessing the infectivity, severity, and immune evasion properties of Omicron are ongoing, understanding the potential scope of Omicron's public health burden is of top priority. (2)

In many European settings, high vaccination rates - particularly among those most at risk of severe disease - have led to a reduction in disease burden. However, protection of the most vulnerable and maintaining low levels of SARS-CoV-2 transmission in the northern hemisphere are currently under threat for multiple reasons. Firstly, indoor contacts are increasing due to the cooler season. Secondly, immunity of the most vulnerable population (people 65+ and those with comorbidities) is potentially waning since they were primarily vaccinated in the first quarter of 2021. Thirdly, relaxation of most non-pharmaceutical interventions (NPIs) since the summer period and fatigue of COVID-19 restrictions has led to increased contacts. The emergence of Omicron combined with these threats calls into question whether current vaccination strategies will be sufficient.

Mathematical models have been used to represent transmission dynamics of SARS-CoV-2 and have supported decision-makers throughout the pandemic on the implementation and relaxation of control strategies. (9-13) Here we further developed and applied OpenCOVID, an individual-based model of SARS-CoV-2 transmission and COVID-19 disease, which includes seasonality patterns, waning immunity profiles, vaccination and NPI strategies, and properties for multiple

variants. (12) We applied the OpenCOVID model to represent a general European setting and simulated the emergence of a novel variant. We analysed disease dynamics for a wide range of infectivity, severity, and immune evasion properties – relative to the Delta VOC – representing a large range of potential Omicron properties. This allowed us to determine the potential for Omicron to become the new dominant variant, and to estimate its potential future public health burden. We further identified combinations of Omicron's properties for which first-generation vaccines, in the absence of strong NPIs, may be sufficient to contain transmission and public health burden (i.e., new SARS-CoV-2 infections, ICU occupancy, and COVID-19 related deaths) and identified those combinations for which additional measures may be required.

Results

Disease dynamics projections

We explored a wide range of potential Omicron infectivity and severity levels (between zero and two) relative to Delta, and the full range of immune evading capacity from 0% (similar to Delta) to 100% (no protection from current vaccines and previously acquired natural immunity after infection). Disease dynamics were simulated over a six-month period beginning 1 December 2021 when Omicron emerged, and the cooler weather arrived. We assume an initial effective reproduction number of 1.2, the absence of strict NPIs (e.g., lockdowns), and vaccination coverage by risk group as described in Supplementary Table 1.

We compared two future vaccination scenarios. Firstly, expanded vaccination, with the administration of a third-dose six months after the second dose for individuals older than 12 years of age, and administration of vaccines for children aged 5-11 years. Secondly, we simulated a scenario with no future vaccine rollout (no third-dose vaccination in over 12-year olds and no vaccination of 5-11 year-olds). The latter leading to decay of population-level vaccine-induced immunity over time.

84 **Drivers of Omicron's potential dominance**

85 Infectivity and immune evasion were identified as the main drivers behind Omicron's potential
86 dominance, with negligible effect from increasing severity. For an infectivity factor of 1, a 25%
87 immune evasion property is predicted sufficient for dominance, while for a 100% immune
88 evading property an infectivity factor of 0.5 (half the infectivity of Delta) is predicted sufficient.
89 All combinations of properties are presented in Supplementary Figure 1-2. When highly
90 immune evading, Omicron's chance to dominate would even slightly increase with future
91 expanded vaccination, as vaccines provide a high level of protection against Delta variant
92 infection (14), consequently increasing the relative susceptibility of the population to Omicron
93 infection.

94 **Disease burden**

95 If Omicron is less infective than Delta (below 1), with no immune evading capacity, it would
96 not become dominant and the public health impact due to its emergence will be negligible
97 (Supplementary Figures 2 -3 and Supplementary Table 2). Assuming Omicron has partial
98 immune evading capacity (20%) and higher infectivity (1.2) and severity (1.5) than Delta, we
99 predict it would take approximately five months for Omicron to become dominant. We predict
100 these properties to lead to a relatively low public health burden, particularly with expanded
101 vaccination. However, in scenarios where Omicron has higher levels of immune evasion
102 capacity (50%), infectivity (1.5), and severity (2) relative to Delta, dominance can occur within
103 two months, resulting in a high projected public health burden. For most combinations of
104 properties Omicron becomes dominant within two to three months, we predict a high to very
105 high impact on disease burden.

106 **Projected impact on peak ICU occupancy**

107 Expanded vaccination is predicted to be sufficient to prevent high ICU occupancy (dark
108 grey/black area of Fig. 1, capped at 25 ICU beds per 100,000 people) for settings in which Delta

remains dominant. For a highly infectious (infectivity factor >1.5) but non-immune-evading variant, we predict expanded vaccination may be sufficient to prevent high ICU occupancy, however this probability diminishes with increasing severity. Moreover, there exists a range of infectivity and immune evading properties for which Omicron becomes dominant, but is not expected to lead to high peak ICU occupancy under the assumption of expanded vaccination (Fig. 1 and dotted area in Fig. 3). Similarly, this range diminishes with increasing severity. For a variant with infectivity and severity similar to Delta, we predict expanded vaccination will be insufficient to prevent high peak ICU occupancy for an immune evading property above 75%. For properties that are predicted to lead to high ICU occupancy, settings would benefit from additional measures such as physical distancing, or new treatments and next generation vaccines as they become available.



Fig. 1: Peak daily ICU occupancy (number of beds per 100,000 population over the six-month simulation period) for a range of variant properties. The threshold (50% prevalence, see Supplementary Figure 3) for Omicron's dominance is presented by red lines (solid for expanded

124 vaccination, dashed for no future vaccination). Expanded vaccination includes third-doses for adults
125 (six-months after second-dose) and vaccinating 5-11-year-olds. Rows represent Omicron's potential
126 severity (0 to 2) relative to Delta (1). Horizontal axes represent the range of Omicron's potential
127 infectivity (0 to 2) relative to Delta (1), left vertical axes Omicron's potential immune evading capacity
128 (0 to 100%). The peak ICU occupancy per 100,000 people has been capped at 25 per 100,000, a much
129 higher ICU capacity than most countries.

130 **Impact on COVID-19 infections and deaths**

131 Omicron's potential severity will have negligible influence on new infections; however, it
132 heavily influences future mortality (in the absence of additional measures that would likely be
133 implemented before such high mortalities (and ICU occupancy) would be reached,
134 (Supplementary Figures 4 and 5). Fig. 2 presents the percentage of infections and deaths averted
135 through expanded vaccinations for all specified combinations of properties. The highest public
136 health burden in terms of infections and deaths (top right corner of Supplementary Figures 4
137 and 5), are least likely to be reduced by expanded vaccination (top right of panels in Fig. 2),
138 because of highly immune evading capacity. However, when Omicron becomes dominant,
139 expanded vaccination has an impact for combinations of properties where immune evasion is
140 low (bottom right of panels in Fig. 2). The benefit of expanding vaccination will also be seen
141 for scenarios where Delta remains dominant (area to the left of the black lines in Fig. 2).



Fig. 2: Percentage of COVID-19 infections and deaths averted by third-dose vaccines for adults and vaccinating 5-11-year-olds with doses one and two. The threshold (50% prevalence) for Omicron's dominance is presented by black lines (solid line for expanded vaccination, dashed for no future vaccination). Left panels represent the percentage infections averted, right panels the percentage of deaths averted due to expanded vaccination, with colour representing % averted. Rows represent Omicron's potential severity (0 to 2) relative to Delta (1), horizontal axes Omicron's potential infectivity (0 to 2) relative to Delta (1) and left vertical axes Omicron's potential immune evading capacity (0 to 100%). Maximum percentage of burden averted is capped at 50%, with blue area extending to values >50%.



Fig. 3: Schematic illustrating a summary of the interplay between potential infectivity, immune evasion of Omicron on its chances of becoming dominant and increasing public health burden.

To aid interpretation of Omicron's properties on its chance of becoming dominant and overall impact on public health burden in a vaccinated population, we summarised our findings in a schematic (Fig. 3). The darkness of colour in the heat map indicates the level of disease burden (infections and deaths) and risk to health systems (ICU occupancy) at the corresponding level of relative infectivity and immune evasion. The dashed line indicates when Omicron would become the dominant variant without future vaccinations, the solid line when it would become dominant with expanded vaccination. The dotted area indicates when Omicron would become dominant without increased disease burden or risk to health systems. Area A indicates variant property space where expanded vaccination alone will not prevent increased transmission and would lead to increased infections, ICU occupancy, and deaths. Additional measures would be needed in the case of very high immune evading variant including second-generation vaccines and/or novel treatment once available, or strengthened NPIs in their absence. Area B indicates space where expanded vaccination with first-generation vaccines will have the highest impact

170 on reducing disease burden and health system risk. In case of low severity in area B, expanded
171 vaccinations may be sufficient for control.

172 Discussion

173 Using our OpenCOVID individual-based transmission model, we simulated the interplay of
174 Omicron's potential combinations of infectivity, severity, and immune evasion properties. We
175 first identified the threshold of Omicron becoming the dominant variant (over Delta), for which
176 infectivity was found to be the main driver followed by immune evasion. Increased disease
177 severity of Omicron was found to have limited effect on dominance, but when dominant, to
178 increase ICU occupancy and number of deaths. If Omicron has increased infectivity and
179 severity to Delta, then expanding first-generation vaccination with a third-dose and vaccinating
180 5-11-year-olds could avert many cases and deaths. However, should Omicron be highly
181 immune evading, first-generation vaccines will not suffice, and additional measures will be
182 required to control transmission until vaccines are updated.

183 Besides additional preventive measures such as strengthened NPIs and second-generation
184 vaccines, new treatments currently under development to reduce ICU occupancy and mortality
185 may need to be implemented. Maximum ICU capacity will have to be considered as it differs
186 between countries, ranging from five to 35 beds per 100,000-population capita in Europe. (15).
187 In a worst-case scenario of highly immune evading and increased severity of Omicron, for many
188 countries, our predictions reach or surpass maximum ICU capacity. However, very high
189 occupancy rates are unlikely to be reached as countries would implement additional measures
190 sooner.

191 Although our analysis focuses on ICU occupancy and mortality as a higher priority public
192 health risk, even rising SARS-CoV-2 infections due to lower severity Omicron may lead to a
193 substantial risk of increased long-COVID (16) and should not be neglected in response

194 planning. Furthermore, as we considered expanding vaccination with third-doses, the global
195 inequity of vaccine access, and the selective pressure and emergence of new variants in settings
196 with low vaccination rates is a global health emergency that needs to be addressed (17).

197 Our transmission model is based on assumptions that influence its outcomes. In our model
198 predictions, we identified that Omicron's potential severity had little effect on the number of
199 new cases, also because no impact on viral load was assumed. Higher viral load in the model is
200 associated with increased transmissibility. The two vaccination scenarios we present in this
201 study, expanded vaccination (with a third-dose for those 12 years of age and older, and two-
202 dose vaccines for children aged 5-11 years) and no future vaccination, are examples of two
203 extreme scenarios. The reality will lie in between and will be region dependent. Waning
204 immunity is assumed to reduce linearly to zero in approximately one year. However, should
205 immunity wane much slower, then the population would be protected for a longer period against
206 either Delta (or a new non-immune evading variant), and our outcomes would prove too
207 pessimistic. Our outcomes would be too optimistic should immunity wane faster than assumed.
208 A higher or lower value of 1.2 for the effective reproduction number at the start of the winter
209 period, prior to introduction of Omicron, may influence peak ICU occupancy estimates,
210 however the relative impact of vaccination is not sensitive to this parameter.

211 SARS-Cov-2 mutations have been identified throughout the pandemic and new variants are
212 likely to continue to emerge. Compared with the Alpha variant, Delta has severity ratios
213 reported as 1.3- to 2.3-times higher for ICU admissions and deaths. (18) Both vaccine-acquired
214 and naturally acquired immunity will not suffice to prevent infection or disease if a new variant
215 is highly immune evading. Based on these predictions we stress that vaccines may need
216 adjustment to respond to current or future viral mutations. We further advocate for continued
217 genomic surveillance and see it crucial to quickly test and continue improving assays that

218 elucidate immune evasion properties of a new VOC, to better understand the risk for increased
219 infectivity and/or severity.

220 **Conclusion**

221 As the properties of Omicron or any future SARS-CoV-2 VOC become known, our analyses
222 elucidate interpretation of the variant's potential dominance and subsequent public health
223 burden. Combined with VOC genomic (19) and population epidemiological surveillance (20),
224 alongside antibody neutralisation testing (21) our findings provide crucial quantitative guidance
225 to decision-makers at a critical time.

226

227 **References**

228 1. Organization WH. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
229 2021 [updated 26 November 2021. Available from: https://www.who.int/news/item/26-11-2021-
230 classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
231 2. Organization WH. Update on Omicron 2021 [Available from:
232 https://www.who.int/news/item/28-11-2021-update-on-omicron.
233 3. Burioni R, Topol EJ. Has SARS-CoV-2 reached peak fitness? Nature Medicine.
234 2021;27(8):1323-4.
235 4. Iftekhar EN, Priesemann V, Balling R, Bauer S, Beutels P, Calero Valdez A, et al. A look into
236 the future of the COVID-19 pandemic in Europe: an expert consultation. The Lancet Regional Health –
237 Europe. 2021;8.
238 5. Commission E. Safe COVID-19 vaccines for Europeans 2021 [Available from:
239 https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-
240 europeans_en.
241 6. Control ECfDPa. SARS-CoV-2 variants of concern as of 3 December 2021 2021 [Available
242 from: https://www.ecdc.europa.eu/en/covid-19/variants-concern.
243 7. Dyer O. Covid-19: South Africa's surge in cases deepens alarm over omicron variant.
244 2021;375:n3013.
245 8. Chen J, Wang R, Benovich Gilby N, Wei G-W. Omicron (B.1.1.529): Infectivity, vaccine
246 breakthrough, and antibody resistance. arXiv e-prints. 2021:arXiv:2112.01318.
247 9. Kerr CC, Stuart RM, Mistry D, Abeysuriya RG, Rosenfeld K, Hart GR, et al. Covasim: An
248 agent-based model of COVID-19 dynamics and interventions. PLOS Computational Biology.
249 2021;17(7):e1009149.
250 10. Hinch R, Probert WJM, Nurtay A, Kendall M, Wymant C, Hall M, et al. OpenABM-Covid19—
251 An agent-based model for non-pharmaceutical interventions against COVID-19 including contact
252 tracing. PLOS Computational Biology. 2021;17(7):e1009146.
253 11. Sonabend R, Whittles LK, Imai N, Perez-Guzman PN, Knock ES, Rawson T, et al. Non-
254 pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a
255 mathematical modelling study. The Lancet. 2021;398(10313):1825-35.
256 12. Shattock AJ, Le Rutte EA, Dünner RP, Sen S, Kelly SL, Chitnis N, et al. Impact of vaccination
257 and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland. medRxiv.
258 2021:2021.04.14.21255503. Under final revisions at Epidemics, pdf provided
259 13. Czyzewski A. Modelling an unprecedented pandemic: The vital role of team-based,
260 collaborative epidemiology and disease modelling in managing pandemics [Available from:
261 https://www.imperial.ac.uk/stories/coronavirus-modelling/.

14. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine. 2021.
15. Bauer J, Brüggmann D, Klingelhöfer D, Maier W, Schwettmann L, Weiss DJ, et al. Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19. Intensive Care Med. 2020;46(11):2026-34.
16. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626-31.
17. Organization WH. Vaccine Equity 2021 [Available from: https://www.who.int/campaigns/vaccine-equity.
18. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. medRxiv. 2021:2021.07.05.21260050.
19. Robishaw JD, Alter SM, Solano JJ, Shih RD, DeMets DL, Maki DG, et al. Genomic surveillance to combat COVID-19: challenges and opportunities. The Lancet Microbe. 2021;2(9):e481-e4.
20. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 2021;375:n2943.
21. News N. Omicron likely to weaken COVID vaccine protection 2021 [updated 08 December 2021. Available from: https://www.nature.com/articles/d41586-021-03672-3.

Methods

OpenCOVID individual-based model

OpenCOVID is a stochastic, discrete-time, individual-based transmission model of SARS-CoV-2 infection and COVID-19 disease (12). The model simulates viral transmission between infectious and susceptible individuals that come in contact through an age-structured, small-world network. The probability of transmission in each exposure is influenced by the infectiousness of the infected individual the immunity of the susceptible individual (acquired through previous infection and/or vaccination), and a background seasonality pattern (reflecting a larger proportion of contacts being in closer contact indoors with cooler temperatures). Infectiousness is a function of viral variant infectivity and time since infection (which follows a gamma distribution peaking approximately at the time of symptom onset). Once infected, a latency period is followed by a pre-symptomatic stage, after which the individual can experience asymptomatic, mild, or severe infection. Severe cases can lead to hospitalisation, ICU admission, and ultimately death. Recovery after infection leads to development of immunity. This immunity is assumed to wane over time and can be further reduced if exposed to a novel variant with immune evading properties (Supplementary Table 2 for further details).

297 The model has the capacity to represent a number of containment measures, including non-
298 pharmaceutical interventions such as social distancing and facemask usage, testing strategies
299 such as test-diagnose isolate, mass-testing, and contact tracing, and also pharmaceutical
300 interventions such as vaccination and treatment.

301 Detailed model descriptions and model equations are described in. (12) Open access source-
302 code for the OpenCOVID model is publicly available at
303 (https://github.com/SwissTPH/OpenCOVID).

304 **Vaccination**

305 In this analysis, we simulate the impact of mRNA vaccines Pfizer/BioNTech and Moderna,
306 which together make up 78% of the total number of doses secured in Europe. (5) Fully
307 susceptible, partially susceptible, and infected individuals not in hospital are considered eligible
308 to receive a vaccine. Vaccines have a two-fold effect; first, they provide protection against new
309 infection through development of immunity (90% transmission blocking effect modelled).
310 Secondly, once infected, vaccines reduce the probability of developing severe symptoms,
311 leading to reduced hospitalisations, ICU admissions, and deaths. Details regarding targeted
312 vaccination groups and assumed durations between doses and vaccine efficacies are described
313 in the Supplementary Information 2.2-2.3. Associated waning immunity profiles after infection
314 and vaccination are described in Supplementary Information 2.4.

315 **Variant properties**

316 Delta (B.1.617.2) is assumed to be the dominant transmission variant at the time of Omicron
317 (B.1.1.529) emergence. A full factorial range of Omicron properties were considered:1)
318 infectivity (transmission multiplication factor per exposure relative to Delta), ranging from 0 to
319 2, 2) disease severity (multiplication factor per infection, relative to Delta ranging from 0 to 2),
320 and 3) immune evasion capacity from 0-100%.. In the model, once infected with a new variant,
321 severity influences the chance to manifest severe symptoms, rather than mild or no symptoms.

322 One hundred percent immune evasion means fully evading any previously naturally or
323 vaccination-acquired immunity, making an individual susceptible to infection with a new
324 variant. Full model details on the variant properties are described in Supplementary Information
325 2.5 alongside probabilities that immunologically naïve infected with develop severe disease in
326 Supplementary Table 3.

327 **Model initialisation**

328 All model simulations were designed to be pseudo-representative of a European setting at the
329 beginning of December 2021. We assume 30% of the population have been previously infected
330 with SARS-CoV-2 over a 630 day period (representing epidemic outbreak in Europe in March
331 2020). We assume the effective reproduction number ($R_e(\tau)$) on 1 December 2021, is equal to
332 1.2. This represents an average scenario of increasing case numbers across Europe at the start
333 of the winter period prior to the emergence of Omicron. This level of $R_e(\tau)$ is lower than levels
334 in some European countries with strongly increasing cases as of early December, however also
335 higher than those that implemented strong NPI before 1st December. The average number of
336 daily contacts required to achieve an $R_e(\tau)$ of 1.2 inherently considers any non-pharmaceutical
337 interventions in place at the beginning of the winter period in Europe prior to the emergence of
338 Omicron. Seasonality is assumed to follow a cosine function, with a peak in seasonal infectivity
339 occurring 6 weeks from model initialisation (representing mid-winter see Supplementary
340 Information Figure 6).

341 **Analyses**

342 For the full range of variant properties specified, we simulated two vaccination scenarios from
343 the introduction of the new variant to six months into the future. For the first scenario, no future
344 vaccinations are implemented. The second scenario is identical up to 1 December 2021, but
345 simulates expanded vaccination with first-generation vaccines administering as third-doses in
346 adults (six months after second-dose) and scale up of first- and second-dose in 5-17 year-olds.

Each simulation provided the relative prevalence of Omicron over the next 6 months compared with Delta, as well as daily and cumulative numbers of new SARS-CoV-2 infections, maximum ICU occupancy, and COVID-19-related deaths. To reflect the element of chance that naturally occurs in transmission dynamics, 10 random stochastic simulations were performed per scenario for which we present the mean. In this analysis we do not explore the effect of varying NPI intensity over time. As such, our analysis reflects predicted disease dynamics and public health burden in the absence of strong NPIs, such as lockdowns.

Data availability statement

Data sharing is not applicable to this article as no datasets were generated or analysed during the study. Data informing model parameters are described in Shattock *et al*. (12)

Code availability statement

All model code and Figure code are open access and publicly available at (https://github.com/SwissTPH/OpenCOVID). For this paper model code and Figure code are version 2.0 of OpenCovid .

Acknowledgements

The authors want to acknowledge and thank the members of the Disease Modelling Unit, Swiss Tropical and Public Health Institute. Calculations were performed at sciCORE (http://scicore.unibas.ch/) scientific computing core facility at University of Basel

Author contributions

EALR and AJS conceived the study, performed the analyses, prepared figures, and conducted model and analysis validation. AJS further developed the model with input from EALR, SLK, and MAP. All authors contributed to interpretation of the results, writing the draft, and final version of the manuscript, and gave final approval for publication.

Competing interests

The authors declare no competing interests.

Funding

Funding for the study was provided by the Botnar Research Centre for Child Health (to MAP) and the Swiss National Science Foundation Professorship of MAP (PP00P3_17070).

Supplementary Information:

Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden

Epke A Le Rutte PhD[*] [a,b], Andrew J Shattock PhD[*] [a,b], Nakul Chitnis PhD [a,b], Sherrie L Kelly PhD [a,b], Melissa A Penny PhD [a,b]

[a] Swiss Tropical and Public Health Institute, Basel, Switzerland

[b] University of Basel, Basel, Switzerland

[*] These authors contributed equally to this work

Correspondence to Prof Melissa A Penny

melissa.penny@unibas.ch

1. Supplementary Figures 1-6 and Tables 1-3

Supplementary Table 1. Overview of two vaccination scenarios. No future vaccination, and expanded vaccination through third-dose in adults (six months after second-dose) and scale up in 5-17 year-olds with first-generation vaccines. Additional details are provided in section 2.3.

Group	As of 1 December 2021	No future vaccination	Expanded vaccination
65+ or comborbidities	90% coverage	90% coverage	90% coverage of third dose* 180 days after second dose
Adults 18-64	70% coverage	70% coverage	70% coverage of third dose* 180 days after second dose
Adolescents 12-17	50% coverage	50% coverage	Scale up to 70% coverage within 2 months
Children 5-11	0% coverage	0% coverage	Scale up to 50% coverage within 4 months
Total number of doses in future		zero	16,000 per 100,000 people over six-months

*5% dropout included between those receiving second and third-dose (95% acceptance rate for third dose for these with two doses)

Supplementary Table 2. Summary of seven combinations of Omicron's potential properties including infectivity, severity, and immune evasion. Probability of Omicron becoming the dominant variant, associated public health burden of Omicron emergence, and the effect of expanded vaccination through third-dose in adults (six months after second-dose) and scale up in 5-17 year-olds with first-generation vaccines.

Simulation	Infectivity (relative to Delta)	Severity (relative to Delta)	Immune evasion	Probability of Omicron dominance	Public health impact	Expanded vaccination* effect
1	1	1	0%	Low	Negligible	High
2	2	1	0%	Very high	High	High
3	2	2	0%	Very high	High	Very high
4	1	1	100%	Very high	High	Moderate
5	1.2	2	20%	High	Low	Moderate
6	1.5	2	50%	Very high	High	Low
7	2	2	100%	Very high	Very high	Negligible

*** Expanded vaccination through third-dose in adults and vaccinating 5-17 year-olds with first-generation vaccines**



Supplementary Figure 1. Temporal epidemiological trends for seven combinations of Omicron's potential properties under no future vaccination. Public health burden is represented by COVID-19 infections and ICU occupancy per 100,000 population per day. Variant prevalence percentage over time is presented in the bottom row.



Supplementary Figure 2. Temporal epidemiological trends for seven different combinations of Omicron's potential properties under expanded vaccination. This figure represents a setting with future expanded vaccination through third-dose in adults (six months after second-dose) and scale up in 5-11 year-olds with first-generation vaccines. Public health burden is represented by COVID-19 infections and ICU occupancy per 100,000 population per day. Variant prevalence percentage over time is presented in the bottom row.



Supplementary Figure 3. The projected prevalence of the Omicron variant under combinations of infectivity, immune evasion capacity, and severity after six months. Black line represents the threshold (50%) for Omicron to become dominant (areas to the right of the lines). Left column represents a setting with expanded vaccination through third-dose in adults (six months after second-dose) and scale up in 5-17 year-olds with first-generation vaccines. Right column represents a setting with no future vaccination. Horizontal axes represent the range of Omicron's potential infectivity (0 to 2) relative to Delta (1). Vertical axes represent the range of Omicron's (or a new VOC's) potential immune evasion capacity (0 to 100%). Rows represent five levels of Omicron's potential severity (0 to 2) relative to Delta (1).



Supplementary Figure 4. Cumulative number of SARS-CoV-2 infections (per 100,000 population over the six-month simulation period) for a wide range of variant properties. Solid and dashed black lines represent the threshold (50%) for Omicron to become dominant (area to the right of the black line). Left panels represent a setting with expanded vaccination with first-generation vaccines through third-dose in adults (six months after second-dose) and scale up in 5-17 year-olds, right panels, a setting with no future vaccination. Horizontal axes represent the range of Omicron's potential infectivity (0 to 2) relative to Delta (1). Left vertical axes represent the range of Omicron's potential immune evasion capacity (0 to 100%). Rows represent five levels of Omicron's potential severity (0 to 2) relative to Delta (1).



Supplementary Figure 5. Cumulative number of COVID-19-related deaths (per 100,000 population over the six-month simulation period) for a wide range of variant properties. Solid and dashed black lines represent the threshold (50%) for Omicron to become dominant (area to the right of the black line). Left panels represent a setting with expanded vaccination through third-dose in adults (six months after second-dose) and scale up in 5-17 year-olds using first-generation vaccines, right panels, a setting with no future vaccination. Horizontal axes represent the range of Omicron's potential infectivity (0 to 2) relative to Delta (1). Left vertical axes represent the range of Omicron's potential immune evasion capacity (0 to 100%). Rows represent five levels of Omicron's potential severity (0 to 2) relative to Delta (1).



Supplementary Figure 6. Predicted temporal epidemiological trends for Delta in the absence of Omicron under no future vaccination and expanded vaccination, alongside seasonality profile. Public health burden is represented by COVID-19 infections, ICU occupancy and COVID-19 related mortality per 100,000 population per day. Seasonal infectious and susceptible population over time is presented in the bottom row. Blue illustrates dynamics with expanded vaccination, and red with no future vaccination.

2. Supplementary methods

2.1 Model initialisation

All model simulations were designed to be pseudo-representative of a general Western European setting at the beginning of December 2021. We assume 30% of the population have been previously infected with SARS-CoV-2 over a 630 day period (representing epidemic outbreak in Europe in March 2020). We assume the effective reproduction number on 1 December 2021 is equal to 1.2. This represents increasing case numbers across Europe at the start of the winter period, prior to the emergence of Omicron. The average number of daily contacts required to achieve an initial effective reproduction number of 1.2 inherently considers any non-pharmaceutical interventions in place at the beginning of the winter period in Europe prior to the emergence of Omicron. Seasonality is assumed to follow a cosine function, with a peak in seasonal infectivity occurring 6 weeks from model initialisation (representing mid-winter, Supplementary Figure 6).

2.2 Vaccine rollout

Four distinct risk groups are simulated for vaccination rollout; those 65 years of age and older or live with comorbidities (high-risk group), all other adults (18-64-year-olds), adolescents (12-17-year-olds), and children (5-11-years-olds). In our simulations, vaccinations start in the high-risk group in January 2021 reaching a 90% coverage rate on 1 December 2021. The 18-64-year-olds start vaccination on 1 May 2021, achieving 70% coverage on 1 December 2021. Adolescents 12-17 years of age started vaccinations on 1 October 2021 with a coverage of 50% achieved by 1 December 2021. Children 5-11 years of age start vaccinations of doses 1 and 2 on 1 December 2021 and are only included as part of the extended vaccination scenario.

Vaccination groups, associated vaccination coverages as of 1 December 2021, and the simulated future scenarios are summarized in Supplementary Table 1.

2.3 Vaccine-induced immunity profile

We model an interval of 28 days between the first and second dose, and a maximum of 95% vaccine efficacy to be reached 14 days after the second dose (increasing with a sigmoidal curve). We assume that 90% of vaccination effect is transmission blocking. We assume vaccinated individuals will always be administered two doses and assume that 95% of those vaccinated with doses one and two will accept a third-dose. Third-doses are administered 6 months after the second dose, after which the maximum vaccine efficacy of 95% is again reached.

2.4 Immunity following infection

After recovering from infection with SARS-CoV-2, individuals develop naturally acquired immunity with a maximum level of 90% transmission blocking effect which they maintain for a month, after which their immunity wanes linearly to zero over a period of 335 days [1,2]. The level of immunity is the reverse of the susceptibility of the individual, which thus increases over time. Immunity immediately after vaccination is also considered 90% in the model, protection against infection, starting two weeks after the second dose has been administered. One month after the second dose, immunity wanes linearly to zero in 335 days.

2.5 Effect of variant properties on prognosis

The probabilities of 1) a symptomatic case developing severe disease, 2) a severe case becoming critical, and 3) a critical case ultimately leading to death, are all defined as functions of age. For this study, we use functions fitted to the probabilities reported in [3], updated to represent the additional risk of hospitalisation from infection with VOC Delta (B.1.617.2) [4-6]. In additional to age-related risk, the probability that an infected individual will develop severe symptoms is also scaled by the severity factor of the viral variant exposed to.

In this study we use a severity factor of 1 for VOC Delta (B.1.617.2), and consider a range of potential relative severity factors for VOC Omicron (B.1.1.529) between 0 and 2. That is, a variant that has 0%-200% severity of Delta. For vaccinated individuals that become infected (noting that the transmission-blocking action of the vaccine reduces the probability of infection), the probability of developing severe disease is reduced by the disease-blocking action of the vaccine. The level to which the probability of severe disease is reduced is dependent upon the level of immunity at the time of infection.

Vaccine-induced immunity is assumed to wane over time and can be further decreased if exposed to a variant with immune evading capacity. In this study, we consider the full range of potential immune evading properties of Omicron, from 0% to 100%. For this study, the probabilities that immunologically naïve (i.e., unvaccinated, and previously uninfected) individuals with no comorbidities infected with Delta (severity factor 1, 0% immune evading) develop severe disease are given in Supplementary Table 3.

Supplementary Table 3. Probabilities that immunologically naïve (i.e., unvaccinated and previously uninfected) individuals with no comorbidities infected with Delta (severity factor 1, 0% immune evading) develop severe disease (source [3-6])

Age group	Severe disease (Delta, unvaccinated)
0-10	<1.0%
10-20	1.0%
20-30	1.2%
30-40	2.4%
40-50	3.9%
50-60	6.6%
60-70	16.3%
70-80	26.0%
80-90+	33.0%

3. References

1 Wheatley, A. K. *et al.* Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat Commun* **12**, 1162, doi:10.1038/s41467-021-21444-5 (2021).

2 Cohen, K. W. *et al.* Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. *Cell Rep Med* **2**, 100354, doi:10.1016/j.xcrm.2021.100354 (2021).

3 Shattock, A. J. *et al.* Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland. *medRxiv*, 2021.2004.2014.21255503, doi:10.1101/2021.04.14.21255503 (2021).

4 Twohig, K. A. *et al.* Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis*, doi:10.1016/s1473-3099(21)00475-8 (2021).

5 Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461-2462, doi:10.1016/s0140-6736(21)01358-1 (2021).

6 CDC. Risk for COVID-19 Infection, Hospitalization, and Death By Age Group. (Atlanta, 2021).